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Worldwide, tuberculosis (TB) remains one of the top 10 causes 
of death, with drug-resistant (DR) TB continuing to be a public 
health crisis.[1] Despite huge investments in combating this highly 
infectious disease, the 2019 Global Tuberculosis Report[1] indicates 
that new cases of DR TB are being reported at an alarming rate, 
with low treatment success rates, high loss to treatment follow-up 
and high death rates. Bedaquiline (BDQ) and delaminid, two new 
medicines developed in the past five decades, and repurposed 
medicines such as linezolid (LZD) and clofazimine (CFZ), form 
the backbone of new regimens aimed at improving treatment 
outcomes.[2-4] South Africa (SA) has made bold decisions to roll 
out new and repurposed medicines as well as a novel short-course 
injection-free regimen that aims to improve patient outcomes.[5] 
In order to improve access to the new and repurposed medicines, 
registration with regulatory authorities has been fast-tracked despite 
low-quality safety and efficacy data generated under research 
conditions or compassionate-use models.[6,7] The World Health 
Organization (WHO) recommends active drug safety monitoring 
and management as new and repurposed medicines are rolled 
out. [8] The focus of monitoring is on adverse events, defined as 
any untoward medical occurrence that may present in a TB patient 
during treatment with a pharmaceutical product, but does not 
necessarily have a causal relationship with this treatment.[8]
Recent WHO updates on the clinical management of DR TB have 
reclassified CFZ from a group 5 medicine with unclear safety and 
efficacy to a core medicine as part of a DR TB treatment regimen. [9-12] 
SA is currently reviewing its guidelines to include CFZ as a core 
medicine to treat multidrug-resistant TB, despite CFZ not being 
registered or included in published SA standard treatment guidelines 
and essential medicines lists.[13,14] Special authorisation is obtained 
from the South African Health Products Regulatory Authority to 
import CFZ into SA for use in DR TB.[15,16] Evidence of safety and 
the optimal effective dose of CFZ in the SA population are lacking to 
inform registration.
In order to ensure the benefits of including new and repurposed 
medicine in the DR TB treatment regimen, the optimal dose must be 
established, with a strong focus on safety.[8] The optimal (effective and 
safe) dose of CFZ is still under debate, with most articles citing this 
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Background. Optimal drug levels and minimal toxicity are critical factors in improving treatment outcomes for patients prescribed new 
and repurposed medicine for drug-resistant (DR) tuberculosis (TB). The optimal dose and dose-related safety of clofazimine (CFZ), a 
repurposed medicine for DR TB, in the South African (SA) population are unknown.
Objectives. To report on dose-related adverse events in patients receiving CFZ plus a background regimen for DR TB.
Methods. In a retrospective review of patient folders from 2012 to 2014, adverse events documented for patients receiving high- (≥200 mg) 
and low-dose (100 mg) CFZ in a centralised DR TB hospital in KwaZulu-Natal Province, SA, were investigated for an association between 
dose-weight interactions and adverse events.
Results. Of 600 patients included, 78.7% (n=472) weighed ≥50 kg. Of these, 17.4% (n=82) received 100 mg CFZ and 82.6% (n=390) 
received >200 mg. Of 128 patients (21.3%) who weighed <50 kg, 68.0% (n=87) received 100 mg CFZ and 32.0% (n=41) received ≥200 mg. 
Of 463 patients (77.2%) who were HIV-positive, 94.0% were on antiretrovirals. There was no difference between the dose-weight cohorts 
in the background regimen given in addition to high- or low-dose CFZ. The frequency and types of adverse events observed were similar 
to the published literature. When analysed per dose-weight cohort, patients weighing <50 kg and receiving high-dose CFZ (≥200 mg) had 
a 2.6 times higher risk of any adverse event (adjusted odds ratio (aOR) 2.57; 95% confidence interval (CI) 1.02 - 6.05; p=0.05: reference 
category <50 kg and 100 mg). Patients weighing <50 kg and receiving high-dose CFZ had a 3.3 times higher risk of gastrointestinal adverse 
events than patients weighing <50 kg and receiving 100 mg CFZ (aOR 3.30; 95% CI 1.51 - 7.19; p=0.003). A high risk of chest pain was 
observed in patients receiving high- and low-dose CFZ, irrespective of weight. Patients weighing <50 kg receiving high-dose CFZ had a 
slightly higher risk of adverse events related to the skin (aOR 1.2; 95% CI 0.55 - 2.62; p=0.7) There were no documented reports of the 
CFZ dose being reduced or the drug being stopped due to adverse events in the sample population.
Conclusions. There is an association between dose-weight interaction and adverse events. The odds of any adverse event occurring were 
higher when low-weight patients (<50 kg) received high-dose CFZ (≥200 mg). Gastrointestinal and skin-related adverse events were more 
common when high-dose CFZ was used in patients weighing <50 kg. Chest pain was reported in patients receiving high- and low-dose CFZ, 
irrespective of weight, and may be a symptom of cardiac toxicity. Plasma concentrations of CFZ may be affected by drug-drug interactions, 
so active drug safety monitoring including electrocardiograms is recommended routinely when CFZ is part of the regimen.
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as an area for further research.[9,12,17-19] The dose of CFZ prescribed 
across studies ranges from 50 mg to 300 mg, with many studies not 
reporting the dose used. All systematic reviews concluded that the 
optimal dose of CFZ requires further investigation.[18,20] Population-
based pharmacokinetics must be considered when making decisions 
on the optimal dose of CFZ to include in the SA DR TB guidelines.
The unique pharmacokinetic properties of CFZ have been widely 
documented, with many studies reporting an unclear mechanism 
of action, a lag in absorption, low serum concentrations even in 
the setting of adequate tissue concentrations, a long terminal half-
life, and interpatient variability in absorption, distribution and 
elimination, which have implications for the treatment regimen. [21-25] 
Schaad-Lanyi et al.[24] suggested that in order to avoid the long-
lasting accumulation towards steady state, higher daily loading 
doses are recommended at the beginning of therapy, followed by 
a daily maintenance dose. A recent study on the impact of CFZ 
dosing on treatment shortening in a mouse model suggests that 
CFZ at low exposures may have negative impacts on treatment 
outcomes, an effect that was evident only after the first 3 months of 
treatment. [26] Previous WHO guidance documents recommended 
weight-based dosing of CFZ, which was adopted globally.[9-12] The 
current published SA treatment guidelines for DR TB include CFZ at 
high doses (200 mg in patients weighing <50 kg and 300 mg in those 
weighing ≥50 kg) for long periods of time (18 - 20 months) in pre-
extensively drug-resistant and extensively drug-resistant TB.[27] This 
decision was made despite there being no conclusive evidence on the 
safety and efficacy of CFZ at high doses for long periods of time in 
the SA population. Concerns and debate regarding the overlapping 
toxicity associated with the use of CFZ, BDQ and fluoroquinolones 
have emerged, and it is important to provide evidence of the safety of 
CFZ at different doses.[7,28-30] No studies have reported on the impact 
of different doses of CFZ on safety and efficacy. Weighing the risk-
benefit of varying doses of CFZ is important to ensure that the dose 
prescribed is able to achieve minimum inhibitory concentrations, 
thus preventing further resistance from emerging, and is safe.
Objectives
To determine the association between the dose of CFZ prescribed at 
different weight bands and the chance of any adverse event occurring 
in the SA population.
Methods
This was a retrospective cohort study of adult patients in KwaZulu-
Natal Province, SA, treated between 2012 and 2014 with a CFZ-
containing regimen for DR TB at doses ranging from low (100 mg) to 
high (≥200 mg). Patients were selected from the pharmacy database, 
in which all patients initiated on a CFZ-containing regimen were 
recorded. The database was reviewed for duplicate entries, and adult 
patients aged ≥18 years with a traceable DR TB number that enabled 
retrieval of their clinical folder were selected. Patients who met the 
study inclusion criteria of age ≥18 years, bacteriologically confirmed 
rifampicin-resistant TB, and availability of a clinical folder with 
treatment outcomes and dose of CFZ recorded were selected. Of 
the 1 018 patients in the pharmacy database, 600 met the inclusion 
criteria and were included in the study.
Data were extracted using manual data collection forms. In 
addition to reports of adverse events documented in the clinical 
notes, information on the starting dose of CFZ, demographics, HIV 
status and antiretroviral therapy, previous TB history, drug exposure, 
baseline tests, drug resistance patterns, background regimen and 
treatment outcomes at 24 months was collected. Missing information 
was sourced from the National Health Laboratory Service database, 
where applicable. The prescription charts were reviewed for starting 
dose of CFZ as well as any reduction in dose or stoppage of the drug. 
The clinical notes were scrutinised for any reports of adverse events 
experienced. Blood results were checked to assess whether there were 
objective data available to verify the clinical notes made by the doctor. 
Electrocardiograms (ECGs) were reviewed, and in the absence of 
objective data, chest pain was used as a surrogate marker of a possible 
cardiac event.
The results of routine blood tests that should have been done were 
reviewed to assess whether kidney function, liver function or the 
blood system were affected following the start of treatment with CFZ. 
ECG results were sought if available to confirm cardiac events.
The frequency and types of adverse events observed in patients 
receiving 100 mg and ≥200 mg CFZ were compared. Multivariate 
logistic regression analysis compared the risk of any adverse events 
in each cohort, taking into account possible confounders that 
could have contributed to the adverse event. An adverse event was 
defined as a documented side-effect in the patient’s clinical folder, 
irrespective of grading or intervention that affected a body system in 
a negative way.
Statistical analysis
Data were captured into an Excel 2010 spreadsheet (Microsoft Corp., 
USA). Data quality was ensured by double entry using research 
assistants during the data extraction process, with any discordances 
that were identified resolved through verification with the original 
paper records. The validated database was analysed using Stata 
version 13.0 (StataCorp, USA). Patients were stratified into two 
groups: those receiving 100 mg CFZ (low dose) and those receiving 
≥200 mg (high dose). Logistic regression analysis was used to assess 
the effect of risk factors on adverse events experienced by patients. 
Univariate and multivariate statistics, 95% confidence intervals 
(CIs) and p-values were used where appropriate to analyse the data. 
Statistical significance was set at p<0.05.
Ethical considerations
Ethics approval to conduct the study was obtained from the University 
of KwaZulu-Natal Biomedical Research Ethics Committee (ref. 
no. BE466/14). The study was also approved by the KwaZulu-Natal 
Health Research Unit (ref. no. KZ 2015RP43_384).
Results
A total of 600 patients met the inclusion criteria and were included in 
the study population. The demographic and clinical characteristics of 
patients in each dose cohort are indicated in Table 1.
The number of medicines, including CFZ, used in the treatment 
regimens ranged from 5 to 11. The majority of the patients (n=277, 
46.2%) received a combination of 8 medicines including CFZ 
as part of their DR TB treatment regimen, 249 (41.5%) received 
7  medicines, 30 (5.0%) received 9 medicines, 11 (1.8%) received 
10  medicines and 8 (1.3%) received 11 medicines. Medicines 
included in the background regimen with CFZ were pyrazinamide 
(99.5% of patients), fluoroquinolones (moxifloxacin or levofloxacin) 
(99.0%), ethionamide (98.2%), ethambutol (98.5%), terizidone 
(97.7%), aminoglycosides (kanamycin or capreomycin) (95.2%), 
para-aminosalicylic acid (48.5%), isoniazid (17.2%), BDQ (6.0%) 
and LZD (3.2%). There was no difference between the background 
regimens prescribed for patients receiving high- and low-dose CFZ.
Of the patients, 400 (66.7%) had an adverse event documented 
in the clinical folder (Table 2). The majority of documented adverse 
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events occurred in patients weighing <50 kg and receiving ≥200 mg 
CFZ, as documented in Table 2. Adverse events recorded in the clinical 
folders were categorised according to body system. Documented 
adverse events affected the muscular system, gastrointestinal tract, 
eyes, skin, central nervous system, ears, feet, kidneys, heart and liver.
Table 3 depicts the frequency of adverse events per body system in 
patients at different weight bands (<50 kg or ≥50 kg) who received 
100 mg or ≥200 mg CFZ. The most common adverse events recorded 
related to the gastrointestinal tract (n=238, 39.67%), followed by 
chest pain as a surrogate marker of a cardiac event (n=136, 22.7%) 
and skin-related adverse events (n=107, 17.8%).
Weakness, loss of appetite, coughing of blood and dyspnoea were 
recorded and viewed as symptoms of DR TB and not classified as an 
adverse event caused by a medicine.
Multivariate logistic regression analysis was used to assess the risk 
of any adverse event occurring at different dose-weight categories. 
The logistics regression model was also used to assess the risk of 
the top three reported adverse events documented (gastrointestinal 
Table 1. Demographic and clinical characteristics of South African patients (N=600) receiving 100 mg and ≥200 mg CFZ as a total 
daily dose for treatment of drug-resistant tuberculosis
Variable 100 mg ≥200 mg p-value
Sample size, n (%) 169 (28.2) 431 (71.8)
Age (years), median (IQR) 34 (18 - 77) 34 (18 - 80) 0.4
Sex, n (%)
Male 84 (49.7) 209 (48.5) 0.8
Female 85 (50.3) 222 (51.5)
Weight (kg), n (%)
<50 87 (51.5) 41 (9.5) <0.001
≥50 82 (48.5) 390 (90.5)
HIV status, n (%)
Positive 133 (78.7) 330 (76.6) 0.6
Negative 36 (21.3) 101 (23.4)
HIV-positive on ART, n (%) 123 (92.5) 312 (94.5) 0.4
Previous TB history, n (%)
New patient 47 (27.8) 59 (13.7) <0.001
Treatment failed/relapse 122 (72.2) 372 (86.3)
CFZ = clofazimine; IQR = interquartile range; ART = antiretroviral therapy; TB = tuberculosis.
Table 2. Comparison of adverse event or no adverse event documented for patients (N=600) receiving 100 mg and ≥200 mg CFZ, 
stratified by dose and weight band
Dose-weight Any adverse event* (N=400, 66.7%), n (%) No adverse event (N=200, 33.3%), n (%)
100 mg and <50 kg 57 (65.5) 30 (34.5)
100 mg and ≥50 kg 54 (65.9) 28 (34.1)
≥200 mg and <50 kg 34 (82.9) 7 (17.1)
≥200 mg and ≥50 kg 255 (65.4) 135 (34.6)
CFZ = clofazimine.
*Related to any body system.
Table 3. Frequency of adverse events in patients (N=600) receiving 100 mg and ≥200 mg CFZ for drug-resistant tuberculosis, 
stratified by weight <50 kg and ≥50 kg
Body system affected by the 
adverse event
Patients with  
adverse event,  
n (%)*
Patients with adverse event receiving 
100 mg CFZ, n (%)
Patients with adverse event receiving 
≥200 mg CFZ, n (%)
<50 kg ≥50 kg <50 kg ≥50 kg
Gastrointestinal tract 238 (39.7) 31 (13.0) 26 (10.9) 26 (10.9) 155 (65.1)
Chest pain 136 (22.7) 18 (13.2) 21 (15.4) 7 (5.2) 90 (66.2)
Skin 107 (17.8) 11(10.3) 14 (13.1) 9 (8.4) 73 (68.2)
Auditory 92 (15.3) 17 (18.5) 13 (14.1) 5 (5.4) 57 (62.0)
Central nervous system 73 (12.2) 14 (19.2) 12(16.4) 3 (4.1) 44 (60.3)
Feet 82 (13.7) 9 (11.0) 13 (15.9) 7 (8.5) 53 (64.6)
Vision 60 (10.0) 3 (5.0) 6 (10.0) 5 (8.3) 46 (76.7)
Kidney 10 (1.7) 4 (40.0) 1 (10.0) 1 (10.0) 4 (40.0)
Muscular system 55 (9.2) 1 (1.8) 6 (10.9) 42 (76.4) 6 (10.9)
Liver 2 (0.3) 0 1 (50.0) 0 1 (50.0)
CFZ = clofazimine.
*Some patients experienced overlapping adverse events.
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adverse events, cardiac events and adverse events related to the skin). 
Table 4 shows the association between dose of CFZ prescribed per 
weight band and the odds of an adverse event occurring. Table 5 
shows the multivariate analysis related to the gastrointestinal tract, 
Table 6 the multivariate analysis related to chest pain and Table 7 
the association between dose and weight and the risk of skin-related 
adverse events.
Patients weighing <50 kg who received high-dose CFZ (≥200 mg) 
were at an increased risk of experiencing any adverse event. It was 
observed that patients in this weight-dose category were 2.57 times 
more likely to experience an adverse event (aOR 2.57; 95% CI 1.02 - 
6.50; p=0.05). The same dose used in patients weighing ≥50 kg was 
found to be as safe as the reference category.
Patients weighing <50 kg and receiving high-dose CFZ (≥200 mg) 
had a 3.3 times higher risk of gastrointestinal adverse events than 
patients weighing <50 kg and receiving 100 mg CFZ (aOR 3.30; 95% 
CI 1.51 - 7.19; p=0.003). The OR was adjusted for co-administration 
of ethionamide and para-aminosalicylic acid, as these two medicines 
Table 4. Association of any adverse event with dose of CFZ (100 mg and ≥200 mg), stratified by weight bands <50 kg and ≥50 kg
Dose-weight
Outcome OR of adverse event (logistic regression)
Any adverse 
event* (N=400, 
66.7%), n (%)
No adverse  
event (N=200, 
33.3%), n (%)
Unadjusted Adjusted†
OR 95% CI p-value OR 95% CI p-value
100 mg and <50 kg 57 (65.5) 30 (34.5) 1 Ref   1 Ref  
100 mg and ≥50 kg 54 (65.9) 28 (34.1) 1.02 0.54 - 1.92 0.9 1.01 0.54 - 1.91 0.9
≥200 mg and <50 kg 34 (82.9) 7 (17.1) 2.56 1.01 - 6.45 0.047 2.57 1.02 - 6.50 0.05
≥200 mg and ≥50 kg 233 (63.3) 135 (36.7) 0.99 0.61 - 1.62 0.9 1.02 0.61 - 1.62 0.9
CFZ = clofazimine; OR = odds ratio; CI = confidence interval; ART = antiretroviral therapy.
*Some patients experienced overlapping adverse events.
†Adjusted for HIV status and ART.
Table 5. Association of adverse events related to the GIT with dose of CFZ (100 mg and ≥200 mg), stratified by weight bands  
<50 kg and ≥50 kg 
Dose-weight
Outcome OR of adverse event (logistic regression)
GIT adverse event 
(N=238), n (%)
No GIT adverse event 
(N=362), n (%)
Unadjusted Adjusted*
OR 95% CI p-value OR 95% CI p-value
100 mg and <50 kg 31 (35.6) 56 (64.4) 1 Ref. 1 Ref.
100 mg and ≥50 kg 26 (31.7) 56 (68.3) 0.84 0.44 - 1.59 0.6 0.85 0.45 - 1.62 0.6
≥200 mg and <50 kg 26 (63.4) 15 (36.6) 3.13 1.45 - 6.78 0.004 3.30 1.51 - 7.19 0.003
≥200 mg and ≥50 kg 155 (39.7) 235 (60.3) 1.19 0.73 - 1.93 0.71 1.23 0.75 - 2.0 0.4
GIT = gastrointestinal tract; CFZ = clofazimine; OR = odds ratio; CI = confidence interval; ART = antiretroviral therapy.
*Adjusted for co-administration of ethionamide and para-aminosalicylic acid, HIV status and ART. 
Table 6. Association of chest pain with dose of CFZ (100 mg and ≥200 mg), stratified by weight bands <50 kg and ≥50 kg 
Dose-weight
Outcome OR of adverse event (logistic regression)
Chest pain 
(N=136), n (%)
No chest pain 
(N=464), n (%)
Unadjusted Adjusted*
OR 95% CI p-value OR 95% CI p-value
100 mg and <50 kg 18 (20.7) 69 (79.3) 1.27 0.48 - 3.33 0.6 1.38 0.52 - 3.64 0.5
100 mg and ≥50 kg 21(25.6) 61 (74.4) 1.67 0.64 - 4.33 0.3 1.99 0.76 - 5.24 0.2
≥200 mg and <50 kg 7 (17.1) 34 (82.9) 1 Ref.   1 Ref.  
≥200 mg and ≥50 kg 90 (23.1) 300 (76.9) 1.46 0.62 - 3.40 0.4 1.44 0.62 - 3.38 0.4
CFZ = clofazimine; OR = odds ratio; CI = confidence interval; ART = antiretroviral therapy.
*Adjusted for co-administration of bedaquiline and fluoroquinolone, HIV status and ART.
Table 7. Association of adverse drug reactions related to the skin with dose of CFZ (100 mg and ≥200 mg), stratified by weight 
bands <50 kg and ≥50 kg 
Dose-weight
Outcome OR of adverse event (logistic regression)
Skin adverse event 
(N=107), n (%)
No skin adverse 
event (N=493), n (%)
Unadjusted Adjusted*
OR 95% CI p-value OR 95% CI p-value
100 mg and <50 kg 11 (12.6) 76 (87.4) 0.63 0.32 - 1.24 0.2 0.62 0.31 - 1.23 0.2
100 mg and ≥50 kg 14 (17.1) 68 (82.9) 0.89 0.48 - 1.68 0.7 0.89 0.47 - 1.67 0.7
≥200 mg and <50 kg 9 (22.0) 32 (78.0) 1.22 0.56 - 2.67 0.6 1.2 0.55 - 2.62 0.7
≥200 mg and ≥50 kg 73 (18.7) 317 (81.3) 1 Ref.   1 Ref.  
CFZ = clofazimine; OR = odds ratio; CI = confidence interval; ART = antiretroviral therapy.
*Adjusted for gender, HIV status and ART.
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are known to contribute significantly to gastrointestinal adverse 
events.
Patients weighing ≥50 kg and receiving ≥200 mg CFZ had a slightly 
higher risk compared with the reference category, but this was not 
significant (aOR 1.23; 95% CI 0.75 - 2.1; p=0.4).
On multivariate analysis it was observed that there was an increased 
risk of chest pain across weight bands, as indicated in Table 6.
Multivariate analysis indicated that patients of low weight (<50 kg) 
who received high doses of CFZ were at a slightly increased risk of 
adverse events related to the skin (1.2 times higher: aOR 1.2; 95% 
CI 0.55 - 2.62; p=0.7).
Discussion
This is the first study that compares adverse events related to varying 
doses of CFZ used for DR TB treatment in SA patients. The main 
finding was that there is an association between the dose of CFZ 
prescribed at different weight bands and the odds of an adverse 
event occurring. High doses of CFZ (≥200 mg) in patients weighing 
<50 kg were associated with an increased frequency of adverse events. 
A similar correlation between CFZ dosage and adverse events, with a 
decrease in dose found to reduce the severity of the adverse events, was 
previously reported by Xu et al.[23] This was the case for any adverse 
event as well as adverse events related to the gastrointestinal tract and 
skin in our patient population. It was found that CFZ administration 
at any dose (100 mg or >200 mg) at any weight was associated with an 
increased chance of chest pain. A limitation of the study is that ECGs 
are not recommended routinely in patients receiving CFZ as standard 
of care in the guidelines, so this information was not available in the 
majority of the patients’ folders. In the absence of objective tests such 
as an ECG or measurement of cardiac enzymes, chest pain was used 
as a surrogate marker of a possible cardiac adverse event, as this is the 
most common symptom of a cardiac event.
Several studies have assessed the safety and efficacy of CFZ for DR 
TB, with promising results of increased efficacy.[17-20] Doses used in all 
studies ranged from 50 mg to 300 mg, with many studies not reporting 
the doses prescribed. Safety information related to CFZ is available, 
with common side-effects of gastrointestinal and skin-related adverse 
events being reported. Similar common adverse events were found in 
the present study. However, ours is the only study that has focused on 
dose-related adverse events.
The jury is still out with regard to the need for a higher loading 
dose of CFZ followed by a daily maintenance dose, in view of the 
pharmacokinetic properties of CFZ.[12] Studies reporting on the optimal 
(safe and effective) dose of CFZ are lacking. Weight-based dosing was 
suggested by Gopal et al.[18] following a systematic review, and a dose 
of 100 mg/d in patients weighing >33 kg and 50 mg/d in patients 
weighing <33 kg was recommended. It was noted by the authors that 
although the optimal dose of CFZ is unknown, their recommendation 
was based on clinical experience and the published literature.[6] 
Schaad-Lanyi et al.[24] also suggested that in order to avoid the long-
lasting accumulation towards steady state, higher daily loading doses 
are recommended at the beginning of therapy, followed by a daily 
maintenance dose. Previous WHO guidelines for the programmatic 
management of patients with DR TB recommended weight-based 
dosing.[9-11] Current SA guidelines[27] also suggest weight-based dosing 
of CFZ, which is supported by information currently under review that 
emanated from the present study. No studies have been conducted to 
assess dose-related efficacy or adverse events in SA patients.
Study limitations
The study has several limitations. Exclusion of patients from the study 
population owing to incorrect file numbers and the retrospective 
analysis limit the study conclusions. This was identified as a system 
failure, and corrective actions were implemented. The retrospective 
nature of the study relied on the clinicians documenting adverse 
events that patients experienced, which could be incomplete. The 
lack of objective blood results and ECG results made it difficult to 
confirm the adverse events documented.
Despite these limitations, the study contributes important 
knowledge on CFZ dose-related adverse events in a largely HIV-
infected SA cohort with DR TB.
Conclusions and recommendations
This is the first study to provide data on CFZ dose-related adverse 
events in the SA population, and must be taken into consideration 
as SA reviews its DR TB guidelines. The increased risk associated 
with higher doses of CFZ in low-weight patients makes a case for 
active drug safety monitoring as part of standard of care. Routine 
monitoring of patients for cardiac dysrhythmias or QT prolongation 
(i.e. using an ECG), and for electrolyte imbalances (especially 
serum potassium) that can predispose to cardiotoxicity, is also 
recommended in view of the increased risk of chest pain at any dose 
that was reported in this study.
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